Neovacs SA (France) Price on November 26, 2024
| ALNEV Stock | EUR 0.0002 0.0001 33.33% |
If you're considering investing in Neovacs Stock, it is important to understand the factors that can impact its price. As of today, the current price of Neovacs SA stands at 0.0002, as last reported on the 2nd of December, with the highest price reaching 0.0003 and the lowest price hitting 0.0002 during the day. Neovacs SA appears to be out of control, given 3 months investment horizon. Neovacs SA has Sharpe Ratio of 0.026, which conveys that the firm had a 0.026% return per unit of risk over the last 3 months. By analyzing Neovacs SA's technical indicators, you can evaluate if the expected return of 0.6% is justified by implied risk. Please exercise Neovacs SA's Risk Adjusted Performance of 0.0208, mean deviation of 12.47, and Downside Deviation of 33.7 to check out if our risk estimates are consistent with your expectations.
Neovacs Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
Neovacs |
Sharpe Ratio = 0.026
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ALNEV | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 23.28 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.6 actual daily | 11 89% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Neovacs SA is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Neovacs SA by adding it to a well-diversified portfolio.
Neovacs SA Valuation on November 26, 2024
It is possible to determine the worth of Neovacs SA on a given historical date. On November 26, 2024 Neovacs was worth 3.0E-4 at the beginning of the trading date compared to the closed value of 1.0E-4. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Neovacs SA stock. Still, in general, we apply an absolute valuation method to find Neovacs SA's value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Neovacs SA where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Neovacs SA's related companies.
| Open | High | Low | Close | Volume | |
| 0.0002 | 0.0003 | 0.0002 | 0.0002 | 33,103,211 | |
11/26/2024 | 0.0003 | 0.0003 | 0.0001 | 0.0001 | 56,189,872 |
| 0.0002 | 0.0002 | 0.0001 | 0.0002 | 23,959,503 |
| Backtest Neovacs SA | | | Neovacs SA History | | | Neovacs SA Valuation | Previous | Next |
Neovacs SA Trading Date Momentum on November 26, 2024
| On November 27 2024 Neovacs SA was traded for 0.0002 at the closing time. The highest price during the trading period was 0.0002 and the lowest recorded bid was listed for 0.0001 . The volume for the day was 24 M. This history from November 27, 2024 contributed to the next trading day price gain. The overall trading delta to the next closing price was 100.00% . The trading delta at closing time to the current price is 200.00% . |
Neovacs SA Fundamentals Correlations and Trends
By evaluating Neovacs SA's financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Neovacs SA's main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Neovacs financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Neovacs SA Stock history
Neovacs SA investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Neovacs is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Neovacs SA will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Neovacs SA stock prices may prove useful in developing a viable investing in Neovacs SA
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. Neovacs S.A. was founded in 1993 and is based in Paris, France. NEOVACS operates under Biotechnology classification in France and is traded on Paris Stock Exchange. It employs 24 people.
Neovacs SA Stock Technical Analysis
Neovacs SA technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Neovacs SA Period Price Range
Low | December 2, 2024
| High |
0.00 | 0.00 |
Neovacs SA cannot be verified against its exchange. Please verify the symbol is currently traded on Euronext Paris. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Neovacs SA December 2, 2024 Market Strength
Market strength indicators help investors to evaluate how Neovacs SA stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Neovacs SA shares will generate the highest return on investment. By undertsting and applying Neovacs SA stock market strength indicators, traders can identify Neovacs SA entry and exit signals to maximize returns
Neovacs SA Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Neovacs SA's price direction in advance. Along with the technical and fundamental analysis of Neovacs Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Neovacs to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.0208 | |||
| Jensen Alpha | 0.0946 | |||
| Total Risk Alpha | (3.60) | |||
| Sortino Ratio | 0.0061 | |||
| Treynor Ratio | 0.1783 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Additional Tools for Neovacs Stock Analysis
When running Neovacs SA's price analysis, check to measure Neovacs SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neovacs SA is operating at the current time. Most of Neovacs SA's value examination focuses on studying past and present price action to predict the probability of Neovacs SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neovacs SA's price. Additionally, you may evaluate how the addition of Neovacs SA to your portfolios can decrease your overall portfolio volatility.